ViroGates A/S

ViroGates A/S maintains a strong liquidity position, with cash and equivalents amounting to DKK 12.23 million, which significantly exceeds its total liabilities of DKK 6.77 million, resulting in a current ratio of 13.64. The company's liquidity is further supported by a low debt-to-equity ratio of 0.4, indicating a conservative capital structure with minimal reliance on long-term debt.

Despite its strong liquidity, the company reported a net loss of DKK 3.60 million in the latest period, with an operating loss of DKK 3.71 million. This results in a negative return on equity of -26.81% and a return on assets of -17.82%, both of which are below the typical performance metrics for the biotechnology and medical research industry. The company's operating cash flow was negative at DKK 3.80 million, and free cash flow was also negative at DKK 3.60 million, indicating that the company is not currently generating positive cash flows from operations.

ViroGates A/S operates in a single business segment focused on the development and commercialization of diagnostic solutions. The company's revenue is primarily derived from the sale of its diagnostic products, with no significant geographic diversification reported in the latest financial data. The company's revenue concentration in a single product line and geographic market may expose it to higher business risk in the event of market or regulatory changes.

The company's growth trajectory is currently constrained by its financial performance, with a net loss and negative cash flows reported in the latest period. There are no disclosed revenue growth rates or outlooks provided in the available data, and the company's capital expenditures were zero, indicating no significant investment in new projects or expansion. The absence of capital expenditures may suggest a focus on cost control or a lack of immediate growth opportunities.

The risk assessment for ViroGates A/S indicates a low level of liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is also low, as the number of basic and diluted shares outstanding is the same, indicating no dilutive impact from stock options or convertible securities. The company's conservative capital structure and strong cash position further support its low liquidity risk profile.

Recent events and filings for ViroGates A/S do not indicate any material changes in the company's financial or operational status. The company's latest financial results reflect ongoing challenges in achieving profitability, but there are no disclosed events or regulatory actions that would significantly impact its operations or financial position.

Operating income improved 28.1% year-over-year, signaling a meaningful reduction in operational losses for the company.

Net income losses narrowed by 27.5% year-over-year, demonstrating improved profitability trends despite ongoing negative earnings.

The company maintains a low debt-to-equity ratio of 0.4, placing it in the bottom quartile of its cohort.

Cash conversion metrics stand at 1.06, performing above the median of 0.87 for the biotechnology cohort.

Revenue grew 8.4% year-over-year to DKK 5.3 million, indicating modest top-line expansion in the latest period.

The company posted a net loss of DKK 10.4 million in the latest fiscal year, remaining unprofitable.

Operating margin of -3.09% trails the cohort median of -1.98%, indicating weaker operational efficiency than peers.

Net margin of -2.99% is below the cohort median of -1.89%, reflecting persistent profitability challenges.